|
CELG's Net Cash Flow Growth by Quarter and Year
Celgene's Net Cash Flow results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Net Cash Flow Growth Y/Y▼
|
Net Cash Flow Growth Y/Y▼
|
| CELG Net Cash Flow (in millions $) |
FY 2019 |
FY 2018 |
FY 2017 |
FY 2016 |
| IV Quarter |
December |
-
|
1,754.00
|
1,502.00
|
647.30
|
| III Quarter |
September |
2,390.00
|
977.00
|
-1,149.00
|
458.90
|
| II Quarter |
June |
1,781.00
|
-1,316.00
|
1,387.00
|
618.20
|
| I Quarter |
March |
1,199.00
|
-4,194.00
|
-897.00
|
-434.80
|
| FY |
|
5,370.00
|
-2,779.00
|
843.00
|
1,289.60
|
| CELG Net Cash Flow third quarter 2019 Y/Y Growth Comment |
Celgene Corp achieved in the third quarter 2019, above Company average Net Cash Flow surge of 144.63% year on year, to $ 2,390.00 millions.
Among companies who have reported third quarter 2019 results in the Major Pharmaceutical Preparations industry only one Company has achieved higher year on year Net Cash Flow results in the third quarter 2019. While Celgene Corp' s Net Cash Flow doubling of 144.63% ranks overall at the positon no. 79 in the third quarter 2019.
|
| CELG Net Cash Flow ( Y/Y Growth %) |
2019
|
2018 |
2017 |
2016 |
| IV Quarter |
December |
- |
16.78 % |
132.04 % |
- |
| III Quarter |
September |
144.63 % |
- |
- |
-66.9 % |
| II Quarter |
June |
- |
- |
124.36 % |
279.03 % |
| I Quarter |
March |
- |
- |
- |
- |
| FY |
|
- |
- |
-34.63 % |
95.52 % |
CELG Net Cash Flow (Quarter on Quarter Growth %) |
2019
|
2018 |
2017 |
2016 |
| IV Quarter |
December |
- |
79.53 % |
- |
41.05 % |
| III Quarter |
September |
34.19 % |
- |
- |
-25.77 % |
| II Quarter |
June |
48.54 % |
- |
- |
- |
| I Quarter |
March |
-31.64 % |
- |
- |
- |
| FY (Year on Year) |
|
- |
- |
-34.63 % |
95.52 % |
| Net Cash Flow Y/Y Growth Statistics |
| High |
Average |
Low |
| 749.48 % |
63.63 % |
-95.38 % |
| (Dec. 31, 2006) |
|
(Sep. 30, 2007) |
|
|
| Net Cash Flow Y/Y Growth Statistics |
| High |
Average |
Low |
| 749.48 % |
63.63 % |
-95.38 % |
| (Dec. 31, 2006) |
|
(Sep. 30, 2007) |
|
| Net Cash Flow by Quarter for the Fiscal Years 2016, 2017, 2018, 2019 |
Celgene's Q/Q Net Cash Flow Growth
| Net Cash Flow Q/Q Growth Statistics |
| High |
Average |
Low |
| 60229.21 % |
2383.35 % |
-100 % |
| (Sep. 30, 2012) |
|
|
| CELG's III. Quarter Q/Q Net Cash Flow Comment |
Celgene Corp achieved in the III. Quarter 2019 below company average Net Cash Flow jump of 34.19% quarter on quarter, to $ 2,390.00 millions.
Even if the III. Quarter 2019 Net Cash Flow quarter on quarter growth was beneath the ordinary of 2383.35 %, it has been yet promising story, as the III. Quarter improvement, outshines the % Net Cash Flow surge in the III. Quarter 2018
Within Major Pharmaceutical Preparations industry 4 other companies have achieved higher Net Cash Flow quarter on quarter growth. While Celgene's Net Cash Flow growth quarter on quarter, overall rank is 180. |
|
|
|
| Net Cash Flow Q/Q Growth Statistics |
| High |
Average |
Low |
| 60229.21 % |
2383.35 % |
-100 % |
| (Sep. 30, 2012) |
|
|
| CELG's III. Quarter Q/Q Net Cash Flow Comment |
Celgene Corp achieved in the III. Quarter 2019 below company average Net Cash Flow jump of 34.19% quarter on quarter, to $ 2,390.00 millions.
Although the III. Quarter 2019 Celgene's Net Cash Flow Q/Q growth was beneath the average , this has been yet encouraging news, as the current improvement, eclipses the % growth in the III. Quarter 2018
Within Major Pharmaceutical Preparations industry 4 other companies have achieved higher Net Cash Flow quarter on quarter growth. While Celgene's Net Cash Flow growth quarter on quarter, overall rank is 180. |
|
Celgene's 12 Months Net Cash Flow Growth Year on Year
Net Cash Flow TTM Growth |
12 Months Ending
(Sep 30 2019) |
12 Months Ending
(Jun 30 2019) |
12 Months Ending
(Mar 31 2019) |
12 Months Ending
(Dec 31 2018) |
12 Months Ending
(Sep 30 2018) |
| Cumulative Net Cash Flow 12 Months Ending |
$ 7,124.00 |
$ 5,711.00 |
$ 2,614.00 |
$ -2,779.00 |
$ -3,031.00 |
| Y / Y Net Cash Flow Growth (TTM) |
- |
- |
- |
- |
- |
| Year on Year Net Cash Flow Growth Overall
Ranking |
# |
# |
# |
# |
# |
| Seqeuential Net Cash Flow Change (TTM) |
24.74 % |
118.48 % |
- |
- |
- |
| Seq. Net Cash Flow Growth (TTM) Overall
Ranking |
# 305 |
# 146 |
# 0 |
# 0 |
# 0 |
| Cumulative Net Cash Flow growth
Comment |
Celgene saw improvement in Net Cash Flow growth trend, posting cumulative 12 months Net Cash Flow growth of 144.63% year on year, to $ 7,124 millions if the fiscal year would have ended in Sep 30 2019.
Celgene's trailing twelve months Net Cash Flow growth was higher than company's average 105.24% and higher than % growth in Jun 30 2019. And, Celgene realized the fastest Net Cash Flow growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Jun 30 2019 rise was slower at 24.74 % from $5711 millions reported in the period from Jun 30 2019 to Sep 30 2018.
It appears to be stagnation happening, more noticeable as we look at average sequential historic increase what is stronger at63.63% Marco Ricci wrote. In the Sep 30 2019 period, Celgene had cumulative twelve months Net Cash Flow of $ 7,124 millions compare to net cash outflow of $ -3,031 millions a year ago.
Celgene Corp achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. . |
| Net Cash Flow TTM Q/Q Growth Statistics |
| High |
Average |
Low |
749.48 % |
63.63 % |
-95.38 % |
|
|
|
|
|
| Net Cash Flow TTM Y/Y Growth Statistics |
| High |
Average |
Low |
963.5 % |
105.24 % |
-96.05 % |
| (Mar 31 2017) |
|
|
| Net Cash Flow TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 10 |
| Sector |
# 33 |
| S&P 500 |
# 305 |
|
| Cumulative Net Cash Flow growth
Comment |
Celgene saw improvement in Net Cash Flow growth trend, posting cumulative 12 months Net Cash Flow growth of 144.63% year on year, to $ 7,124 millions if the fiscal year would have ended in Sep 30 2019.
Celgene's trailing twelve months Net Cash Flow growth was higher than company's average 105.24% and higher than % growth in Jun 30 2019. And, Celgene realized the fastest Net Cash Flow growth, in Major Pharmaceutical Preparations industry.
But from the previous reporting period rise was slower at 24.74 % from $5711 millions achieved in twelve months ending a quarter Jun 30 2019 Marco Ricci added on.
We witness drop-off developing, more obvious as we look at usual sequential historic increase what is higher at 63.63%.
The growth was even higher sequentially clinched at 24.74 % rise from $5711 millions in twelve months ending a quarter before. In the Sep 30 2019 period, Celgene had cumulative twelve months Net Cash Flow of $ 7,124 millions compare to net cash outflow of $ -3,031 millions a year ago.
Celgene Corp achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. . |
| Net Cash Flow TTM Q/Q Growth Statistics |
| High |
Average |
Low |
749.48 % |
63.63 % |
-95.38 % |
|
|
|
| Net Cash Flow TTM Y/Y Growth Statistics |
| High |
Average |
Low |
963.5 % |
105.24 % |
-96.05 % |
| (Mar 31 2017) |
|
|
| Net Cash Flow TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 10 |
| Sector |
# 33 |
| S&P 500 |
# 305 |
|
212.34%